(Reuters) -The U.S. House Judiciary Committee on Monday subpoenaed a former Pfizer executive after he declined to voluntarily ...

Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average ...

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that there was a conspiracy among ...

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

BRUSSELS (AP) — The president of the European Union’s executive branch, Ursula von der Leyen, faces a no-confidence vote this ...

The Justice Department changed its policy on foreign corruption cases, which might have put an end to investigations into the ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

House Judiciary Chair Jim Jordan subpoenaed Dr. Philip Dormitzer after he refused to testify in the 2020 vaccine delay probe, ...